In the world Bladder Cancer affects 330.000 patients each year. Because there is a 50-70% chance of tumor recurrence, after surgery, bladder cancer patients perform extensive surveillance: every 3 months for 2 years, every 6 months for additional 2 years and once a year after that. Surveillance is currently performed by Cystoscopy: an endoscopic method of examining the bladder by inserting a probe through the urethra. Bladder cancer is the cancer type with the most expensive follow-up: over 160.000 USD per patient/per year. An estimated 1 million bladder cancer patients are under follow-up. We have developed and patented an ultrasensitive assay for detection of a bladder cancer biomarker in urine samples. By performing a non-invasive, urine-based, test for ultrasensitive detection of bladder cancer as a complement to follow-up using cystoscopy, we will alleviate patients from highly uncomfortable procedures, reduce Urologist’s workload and save about 50% of healthcare costs with bladder cancer surveillance.